Clinical trial · Interventional
UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
NCT00578045CI-TRIAL-00019583withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no accrual
Summary
Brief summary (as posted)
The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transfusion | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
- interventionNames
- Procedure: Transfusion
Primary outcomes (1)
- measure
- The researchers on this study want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
- timeFrame
- 12 months
Secondary outcomes (1)
- measure
- The researchers also want to find out what types of side effects, if any, subjects will experience with this treatment.
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced hematological malignancies who have failed at least two lines of therapy. * Karnofsky performance score \> 60, unless due to disease and then \> 50. * Age \> 18 years. * An expected survival of \> 3 months. * Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study. * Cord blood must have negative serology for HIV. * Release of cord blood. * The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight. Exclusion Criteria: * Liver function: total bilirubin \> 2x ULN or AST/ALT \> 3x ULN. * Creatinine \> 3.0 mg/dL.
References
Publications (0)
Data not yet available
No reference posted for this study.